Ressources - Page 30 of 43 - Oncodesign Services

Press release

26/03/2015

Oncodesign signs additional 2-year preclinical research contract to evaluate antibody-drug conjugates

Poster

01/01/2015

EORTC 2015 – Tumor infiltrating lymphocytes as a biomarker of response for CTLA-4 targeting therapies

Poster

01/01/2015

EORTC 2015 – Efficacy of PD-1 / PD-L1 pathway disruptors in syngeneic models

Poster

01/01/2015

AACR 2015 – Evaluation of immuno-oncology related treatment in syngenic mouse models

Poster

01/01/2015

AACR 2015 – In vivo TK-NOG liver-humanized model to predict patient pharmacological profile of anti-cancer agents

In vivo model in Oncology for drug discovery : TK-NOG liver-humanized model to predict patient pharmacological profile of anti-cancer agents.

Poster

01/01/2015

Identification and characterization of a novel LRRK2 kinase inhibitor: ODS2005294

Press release

17/12/2014

Europe – Oncodesign has entered into a services agreement with Eisai to develop a new personalized medicine program in earlier line metastatic breast cancer treatment

Press release

04/11/2014

Oncodesign announces the third extension of a research contract with Isarna Therapeutics

Scientific publication

24/10/2014

In vivo inhibition of RIPK2 kinase alleviates inflammatory disease

Press release

13/10/2014

Oncodesign seals a major research agreement with Cellectis

Press release

29/09/2014

Oncodesign announces the discovery of new molecule inhibitors of inflammatory disease and the publication of 3 new patent applications

Scientific publication

01/09/2014

Steroidal saponins from Dioscorea preussii

Oncodesign signs additional 2-year preclinical research contract to evaluate antibody-drug conjugates

EORTC 2015 – Tumor infiltrating lymphocytes as a biomarker of response for CTLA-4 targeting therapies

EORTC 2015 – Efficacy of PD-1 / PD-L1 pathway disruptors in syngeneic models

AACR 2015 – Evaluation of immuno-oncology related treatment in syngenic mouse models

AACR 2015 – In vivo TK-NOG liver-humanized model to predict patient pharmacological profile of anti-cancer agents

Identification and characterization of a novel LRRK2 kinase inhibitor: ODS2005294

Europe – Oncodesign has entered into a services agreement with Eisai to develop a new personalized medicine program in earlier line metastatic breast cancer treatment

Oncodesign announces the third extension of a research contract with Isarna Therapeutics

In vivo inhibition of RIPK2 kinase alleviates inflammatory disease

Oncodesign seals a major research agreement with Cellectis

Oncodesign announces the discovery of new molecule inhibitors of inflammatory disease and the publication of 3 new patent applications

Steroidal saponins from Dioscorea preussii

Contact-us

Science within easy reach!